

David W Holt

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10453396/publications.pdf>

Version: 2024-02-01

106
papers

4,469
citations

186265

28
h-index

168389

53
g-index

107
all docs

107
docs citations

107
times ranked

3182
citing authors

#	ARTICLE	IF	CITATIONS
1	Discussion: can upper extremity (deltoid) near infrared spectroscopy be used to assess cerebral tissue bed saturation on femorally cannulated veno-arterial extracorporeal membrane oxygenation patients?. <i>Perfusion (United Kingdom)</i> , 2021, 36, 190-199.	1.0	1
2	Quantification of mycophenolic acid in human plasma by liquid chromatography with time-of-flight mass spectrometry for therapeutic drug monitoring. <i>Biomedical Chromatography</i> , 2021, 35, e5011.	1.7	2
3	Alternative Input for Perfusion Management Devices: Voice Recognition for Data Input and the Effects on Charting and Perioperative Calculation Use.. <i>Journal of Extra-Corporeal Technology</i> , 2021, 53, 286-292.	0.4	0
4	Comparison of three infant venous reservoirs with vacuum-assisted venous drainage during varying levels of cardiotomy suction. <i>Perfusion (United Kingdom)</i> , 2020, 35, 26-31.	1.0	2
5	Perfusion Recruitment Strategies Using Choice-Based Conjoint Analysis. <i>Journal of Extra-Corporeal Technology</i> , 2020, 52, 218-226.	0.4	0
6	Improving Decreased Heater-Cooler Efficiency as a Result of Heater-Cooler Infection Control Strategy. <i>Journal of Extra-Corporeal Technology</i> , 2019, 51, 73-77.	0.4	0
7	A herbal treatment for type 2 diabetes adulterated with undisclosed drugs. <i>Lancet, The</i> , 2018, 391, 2411.	13.7	11
8	Colloid Oncotic Pressure, Monitoring its Effects in Cardiac Surgery. <i>Journal of Extra-Corporeal Technology</i> , 2017, 49, 249-256.	0.4	1
9	Therapeutic Drug Monitoring of Everolimus. <i>Therapeutic Drug Monitoring</i> , 2016, 38, 143-169.	2.0	102
10	Assuring the Proper Analytical Performance of Measurement Procedures for Immunosuppressive Drug Concentrations in Clinical Practice. <i>Therapeutic Drug Monitoring</i> , 2016, 38, 170-189.	2.0	95
11	Substandard drugs: a potential crisis for public health. <i>British Journal of Clinical Pharmacology</i> , 2014, 78, 218-243.	2.4	174
12	Standardization of LC-MS for Therapeutic Drug Monitoring of Tacrolimus. <i>Clinical Chemistry</i> , 2013, 59, 1630-1637.	3.2	42
13	The Need for Standardization of Tacrolimus Assays. <i>Clinical Chemistry</i> , 2011, 57, 1739-1747.	3.2	55
14	Case series of individuals with analytically confirmed acute mephedrone toxicity. <i>Clinical Toxicology</i> , 2010, 48, 924-927.	1.9	192
15	Recreational Use of Mephedrone (4-Methylmethcathinone, 4-MMC) with Associated Sympathomimetic Toxicity. <i>Journal of Medical Toxicology</i> , 2010, 6, 327-330.	1.5	185
16	Consensus Report on Therapeutic Drug Monitoring of Mycophenolic Acid in Solid Organ Transplantation. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2010, 5, 341-358.	4.5	276
17	Black renal transplant recipients have poorer long-term graft survival than CYP3A5 expressers from other ethnic groups. <i>Nephrology Dialysis Transplantation</i> , 2010, 25, 628-634.	0.7	25
18	Opportunities to Optimize Tacrolimus Therapy in Solid Organ Transplantation: Report of the European Consensus Conference. <i>Therapeutic Drug Monitoring</i> , 2009, 31, 139-152.	2.0	398

#	ARTICLE	IF	CITATIONS
19	Cardiovascular toxicity associated with recreational use of diphenylprolinol (diphenyl-2-pyrrolidinemethanol [D2PM]). <i>Journal of Medical Toxicology</i> , 2008, 4, 167-169.	1.5	29
20	Dissociative and sympathomimetic toxicity associated with recreational use of 1-(3-trifluoromethylphenyl) piperazine (TFMPP) and 1-benzylpiperazine (BZP). <i>Journal of Medical Toxicology</i> , 2008, 4, 254-257.	1.5	58
21	Detection of the pharmaceutical agent glaucine as a recreational drug. <i>European Journal of Clinical Pharmacology</i> , 2008, 64, 553-554.	1.9	22
22	Pharmacogenetics of immunosuppressive drugs: prospect of individual therapy for transplant patients. <i>Pharmacogenomics</i> , 2008, 9, 585-596.	1.3	22
23	A Pharmacogenetic Strategy for Immunosuppression Based on the CYP3A5 Genotype. <i>Transplantation</i> , 2008, 85, 163-165.	1.0	49
24	First case report of recreational use of 2,5-dimethoxy-4-chloroamphetamine confirmed by toxicological screening. <i>European Journal of Emergency Medicine</i> , 2008, 15, 354-356.	1.1	23
25	Comparing Mycophenolate Mofetil Regimens for de Novo Renal Transplant Recipients: The Fixed-Dose Concentration-Controlled Trial. <i>Transplantation</i> , 2008, 86, 1043-1051.	1.0	238
26	Pharmacogenetics as a tool for optimising drug therapy in solid-organ transplantation. <i>Expert Opinion on Pharmacotherapy</i> , 2007, 8, 2045-2058.	1.8	22
27	Multi-drug resistance gene-1 (MDR-1) haplotypes and the CYP3A5*1 genotype have no influence on ciclosporin dose requirements as assessed by C0 or C2 measurements. <i>Clinical Transplantation</i> , 2007, 21, 252-257.	1.6	31
28	Multidrug Resistance Gene-1 (MDR-1) Haplotypes Have a Minor Influence on Tacrolimus Dose Requirements. <i>Transplantation</i> , 2006, 82, 705-708.	1.0	50
29	An Herbal Remedy for Impotence: More Than Was Bargained For. <i>Journal of Clinical Pharmacology</i> , 2006, 46, 1379-1381.	2.0	4
30	Bioequivalence of Enteric-Coated Mycophenolate Sodium and Mycophenolate Mofetil: A Meta-Analysis of Three Studies in Stable Renal Transplant Recipients. <i>Transplantation</i> , 2006, 82, 1413-1418.	1.0	50
31	Therapeutic Drug Monitoring of Mycophenolate Mofetil in Transplantation. <i>Therapeutic Drug Monitoring</i> , 2006, 28, 145-154.	2.0	305
32	Tacrolimus Pharmacogenetics: The CYP3A5*1 Allele Predicts Low Dose-Normalized Tacrolimus Blood Concentrations in Whites and South Asians. <i>Transplantation</i> , 2005, 79, 499-502.	1.0	178
33	CYP3A5 Genotype Does Not Influence the Blood Concentration of Tacrolimus Measured with the Abbott Immunoassay. <i>Clinical Chemistry</i> , 2005, 51, 2214-2215.	3.2	10
34	Genotyping cytochrome P450 3A5 using the Light Cycler. <i>Annals of Clinical Biochemistry</i> , 2005, 42, 376-381.	1.6	19
35	Does pharmacogenetics have the potential to allow the individualisation of immunosuppressive drug dosing in organ transplantation?. <i>Expert Opinion on Pharmacotherapy</i> , 2005, 6, 2593-2605.	1.8	9
36	The Influence of Pharmacogenetics on the Time to Achieve Target Tacrolimus Concentrations after Kidney Transplantation. <i>American Journal of Transplantation</i> , 2004, 4, 914-919.	4.7	238

#	ARTICLE	IF	CITATIONS
37	Monitoring immunosuppressive drugs. Handbook of Analytical Separations, 2004, , 273-296.	0.8	1
38	Monitoring Immunosuppressive Drugs. Therapeutic Drug Monitoring, 2004, 26, 244-247.	2.0	6
39	The Pharmacogenetics of Immunosuppression for Organ Transplantation. Molecular Diagnosis and Therapy, 2003, 3, 291-301.	3.3	28
40	Pharmacogenomics of immunosuppressive drug metabolism. Current Opinion in Nephrology and Hypertension, 2003, 12, 607-613.	2.0	25
41	Tacrolimus pharmacogenetics: polymorphisms associated with expression of cytochrome p4503A5 and p-glycoprotein correlate with dose requirement. Transplantation, 2002, 74, 1486-1489.	1.0	283
42	International Federation of Clinical Chemistry/International Association of Therapeutic Drug Monitoring and Clinical Toxicology Working Group on Immunosuppressive Drug Monitoring. Therapeutic Drug Monitoring, 2002, 24, 59-67.	2.0	82
43	Therapeutic drug monitoring of immunosuppressive drugs in kidney transplantation. Current Opinion in Nephrology and Hypertension, 2002, 11, 657-663.	2.0	51
44	Monitoring mycophenolic acid. Annals of Clinical Biochemistry, 2002, 39, 173-183.	1.6	55
45	Sources of preanalytical variability in the measurement of biochemical markers of bone turnover. , 2002, , 140-158.		0
46	Prognosis and management of patients with acute liver failure. , 2002, , 199-210.		0
47	Genomics and biomarkers in toxicology. , 2002, , 291-298.		1
48	Evidence-based medicine: evaluation of biomarkers. , 2002, , 3-15.		1
49	Statistical approaches to rational biomarker selection. , 2002, , 24-31.		1
50	Biochemical markers of bone resorption. , 2002, , 122-132.		2
51	Biomarkers of hepatic disease. , 2002, , 167-176.		1
52	Biomarkers in artificial and bioartificial liver support. , 2002, , 211-220.		0
53	Tumour markers in gastrointestinal disease. , 2002, , 272-280.		0
54	The impact of biochemical tests on patient management. , 2002, , 325-333.		0

#	ARTICLE	IF	CITATIONS
55	Monitoring liver transplant recipients. , 2002, , 423-432.		0
56	The early detection of renal impairment in diabetes mellitus. The case for microalbuminuria and other biomarkers. , 2002, , 76-96.		0
57	Genetic approaches to the study of complex diseases: osteoporosis. , 2002, , 159-164.		0
58	IL-6-type cytokines and signalling in inflammation. , 2002, , 256-262.		0
59	Serum markers of inflammation and cardiovascular risk. , 2002, , 345-354.		0
60	An overview of S-100 β as a clinically useful biomarker of brain tissue damage. , 2002, , 406-412.		0
61	Molecular diagnosis of cytomegalovirus disease. , 2002, , 467-473.		0
62	Development of biomarkers: the industrial perspective. , 2002, , 16-23.		0
63	Biomarkers in renal disease. , 2002, , 45-55.		0
64	Biomarkers for evaluating the safety of genetically modified foods. , 2002, , 313-322.		0
65	Cardiac natriuretic peptides in risk assessment of patients with acute myocardial infarction or congestive heart failure. , 2002, , 334-344.		1
66	Diagnosis and monitoring of inflammatory events in transplant recipients. , 2002, , 474-482.		0
67	The clinical significance of markers of coagulation in acute coronary syndromes. , 2002, , 355-364.		0
68	The clinical application of biomarkers in osteoporosis. , 2002, , 133-139.		0
69	Toxicogenetic markers of liver dysfunction. , 2002, , 190-198.		1
70	Endothelin: what does it tell us about myocardial and endothelial dysfunction?. , 2002, , 365-373.		0
71	Biomarkers of neurodegenerative disorders. , 2002, , 391-397.		0
72	Biomarkers of bone formation. , 2002, , 115-121.		1

#	ARTICLE	IF	CITATIONS
73	Homocysteine: a reversible risk factor for coronary heart disease. , 2002, , 374-378.		0
74	Advances in pharmacodynamic biomarkers for monitoring the response to immunosuppressive drug therapy. , 2002, , 442-450.		0
75	Early markers of nephrotoxicity for environmental and occupational monitoring. , 2002, , 66-75.		1
76	The genetics of renal disease. , 2002, , 56-65.		0
77	Prognostic markers in liver disease. , 2002, , 221-227.		0
78	Apoptosis: biomarkers and the key role of mitochondria. , 2002, , 228-238.		0
79	Monitoring heart and lung transplant patients. , 2002, , 415-422.		0
80	Post-transplantation bone disease. , 2002, , 461-466.		0
81	Using intelligent systems in clinical decision support. , 2002, , 32-42.		1
82	Liver regeneration: mechanisms and markers. , 2002, , 239-243.		0
83	Protein profiling and proteomic databases. , 2002, , 299-312.		0
84	Matrix metalloproteinases and their tissue inhibitors. , 2002, , 379-388.		0
85	How pharmacokinetic and pharmacodynamic drug monitoring can improve outcome in solid organ transplant recipients. Transplant Immunology, 2002, 9, 211-214.	1.2	22
86	Bone turnover markers in clinical practice. , 2002, , 99-114.		1
87	The immunogenetics of metabolic liver disease. , 2002, , 177-189.		0
88	Biomarkers in gastrointestinal disease. , 2002, , 265-271.		0
89	Chronic allograft damage index as a surrogate marker for chronic allograft rejection. , 2002, , 433-441.		2
90	Traumatic brain injury: assessment by biochemical serum markers. , 2002, , 398-405.		1

#	ARTICLE	IF	CITATIONS
91	The use of biomarkers for monitoring the response to immunosuppressive drug therapy. , 2002, , 451-460.		0
92	Markers of malabsorption: coeliac disease. , 2002, , 281-288.		0
93	Determinants of responses to viruses and self in liver disease. , 2002, , 244-255.		0
94	Cyclosporine monitoring based on C2 sampling. Transplantation, 2002, 73, 840-841.	1.0	12
95	Elevated serum levels of soluble interleukin-2 receptor, neopterin and β -2-microglobulin in idiopathic dilated cardiomyopathy: relation to disease severity and autoimmune pathogenesis. European Journal of Heart Failure, 2001, 3, 155-163.	7.1	24
96	Current Issues in Therapeutic Drug Monitoring of Mycophenolic Acid: Report of a Roundtable Discussion. Therapeutic Drug Monitoring, 2001, 23, 305-315.	2.0	239
97	Proficiency testing schemes for therapeutics and toxicology. Accreditation and Quality Assurance, 2000, 5, 389-391.	0.8	0
98	Delivering quality for the measurement of immunosuppressive drugs: current performance and future needs. Accreditation and Quality Assurance, 1999, 4, 427-430.	0.8	4
99	Current opinions on therapeutic drug monitoring of immunosuppressive drugs. Clinical Therapeutics, 1999, 21, 1632-1652.	2.5	106
100	Therapeutic monitoring of mycophenolic acid. Clinical Biochemistry, 1998, 31, 317-322.	1.9	118
101	Myocardial Injury Induced by Radiofrequency and Low Energy Ablation: A Quantitative Study of CK Isoforms, CK-MB, and Troponin-T Concentrations. PACE - Pacing and Clinical Electrophysiology, 1998, 21, 1410-1416.	1.2	34
102	Class III Antiarrhythmics in Overdose. Drug Safety, 1993, 9, 450-462.	3.2	25
103	Effects of amiodarone on the kinetics of antipyrine. American Journal of Cardiology, 1989, 63, 991-992.	1.6	3
104	Practical Applications of Therapeutic Drug Monitoring: The impact of technological developments. , 1989, , 93-102.		0
105	Management of cardiac drug overdose. Resuscitation, 1984, 11, 207-216.	3.0	3
106	Amiodarone pharmacokinetics. American Heart Journal, 1983, 106, 840-847.	2.7	415